WASHINGTON--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) announced today the target lesion revascularization (TLR) rate for the company’s Endeavor®drug-eluting stent in the real-world Danish trial, SORT OUT III, was 4.0 percent. This result at nine months is consistent with the ENDEAVOR-Five real-world study, which reported an overall TLR of 4.5 percent at 12 months. The rates of myocardial infarction in the SORT OUT III study were very low for both the Endeavor (1.4 percent) and Cypher (0.5 percent) stents. The rate of stent thrombosis in SORT OUT III for Endeavor was 1.2 percent (ARC definite), consistent with typical rates of stent thrombosis for both drug-eluting and bare-metal stents after nine months of patient follow up.
